Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, r... by Blay, Jean-Yves, Prof, Devin, Quentin, MSc, Duffaud, Florence, Prof, Toulmonde, Maud, MD, Firmin, Nelly, MD, Collard, Olivier, MD, Bompas, Emmanuelle, MD, Verret, Benjamin, MD, Ray-Coquard, Isabelle, Prof, Salas, Sebastien, Prof, Henon, Clemence, MD, Honoré, Charles, MD, Brahmi, Mehdi, MD, Dufresne, Armelle, MD, Pracht, Marc, MD, Hervieu, Alice, MD, Penel, Nicolas, Prof, Bertucci, Francois, Prof, Rios, Maria, MD, Saada-Bouzid, Esma, MD, Soibinet, Pauline, MD, Perol, David, MD, Chabaud, Sylvie, PhD, Italiano, Antoine, Prof, Cesne, Axel Le, MD

Get full text

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, mul... by Mir, Olivier, MD, Cropet, Claire, MSc, Toulmonde, Maud, MD, Cesne, Axel Le, MD, Molimard, Mathieu, Prof, Bompas, Emmanuelle, MD, Cassier, Philippe, MD, Ray-Coquard, Isabelle, Prof, Rios, Maria, MD, Adenis, Antoine, Prof, Italiano, Antoine, MD, Bouché, Olivier, Prof, Chauzit, Emmanuelle, PharmD, Duffaud, Florence, Prof, Bertucci, François, Prof, Isambert, Nicolas, MD, Gautier, Julien, MSc, Blay, Jean-Yves, Prof, Pérol, David, MD

Get full text

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial by Le Cesne, Axel, Dr, Ray-Coquard, Isabelle, MD, Bui, Binh Nguyen, MD, Adenis, Antoine, MD, Rios, Maria, MD, Bertucci, François, MD, Duffaud, Florence, MD, Chevreau, Christine, MD, Cupissol, Didier, MD, Cioffi, Angela, MD, Emile, Jean-François, MD, Chabaud, Sylvie, MsC, Pérol, David, MD, Blay, Jean-Yves, MD

Get full text

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial by Négrier, Sylvie, Prof, Gravis, Gwenaëlle, MD, Pérol, David, MD, Chevreau, Christine, MD, Delva, Rémy, MD, Bay, Jacques-Olivier, Prof, Blanc, Ellen, MSc, Ferlay, Céline, MSc, Geoffrois, Lionnel, MD, Rolland, Frédéric, MD, Legouffe, Eric, MD, Sevin, Emmanuel, MD, Laguerre, Brigitte, MD, Escudier, Bernard, MD

Get full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label,... by Paz-Ares, Luis, Prof, Ciuleanu, Tudor-Eliade, MD, Cobo, Manuel, MD, Schenker, Michael, MD, Zurawski, Bogdan, MD, Menezes, Juliana, MD, Richardet, Eduardo, MD, Bennouna, Jaafar, MD, Felip, Enriqueta, Prof, Juan-Vidal, Oscar, Prof, Alexandru, Aurelia, MD, Sakai, Hiroshi, MD, Lingua, Alejo, MD, Salman, Pamela, Prof, Souquet, Pierre-Jean, MD, De Marchi, Pedro, MD, Martin, Claudio, MD, Pérol, Maurice, MD, Scherpereel, Arnaud, Prof, Lu, Shun, Prof, John, Thomas, MD, Carbone, David P, Prof, Meadows-Shropshire, Stephanie, PhD, Agrawal, Shruti, PhD, Oukessou, Abderrahim, MD, Yan, Jinchun, MD, Reck, Martin, Prof

Get full text